Opening https://www.prnewswire.com/news-releases/bridgebio-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-bbp-398-a-potentially-best-in-class-shp2-inhibitor-in-combination-with-opdivo-nivolumab-in-advanced-solid-tumors-with-kras-mutations-301341605.html